Exchange: NYSEArca·Updated 07:30 PM EST

BBP News

News
all
press releases
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks
More News
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Zacks
Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.
Zacks
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
Zacks
The company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.
Stocktwits
Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.
Stocktwits
Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.
Stocktwits
The company said it plans to submit a biologics license application by the fourth quarter of 2026.
Stocktwits
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Zacks
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
Zacks

Advertisement|Remove ads.